

Article Untargeted Metabolite Profiling Reveals Acute Toxicity of Pentosidine on Adipose Tissue of Rats

Chuanqin Hu¹, Zhenzhen Shao¹, Wei Wu¹ and Jing Wang^{2,*}

- ¹ School of Light Industry Science and Engineering, Beijing Technology and Business University (BTBU), 11 Fucheng Road, Beijing 100048, China; huchuanqin@btbu.edu.cn (C.H.)
- ² Key Laboratory of Geriatric Nutrition and Health, Beijing Technology and Business University, Ministry of Education, Beijing 100048, China
- * Correspondence: wangjing@th.btbu.edu.cn; Tel.: +86-010-68985334; Fax: +86-010-68985378

Abstract: Background: Pentosidine is an advanced glycation end product that is commonly found in heat-processed foods. Pentosidine has been involved in the occurrence and development of some chronic diseases. It was reported that pentosidine exposure can impair the function of the liver and kidneys. Adipose tissue, as an active endocrine organ, plays an important role in maintaining the normal physiological function of cells. However, the metabolic mechanism that causes pentosidine to induce toxicity in adipose tissue remains unclear. Methods: In the study, thirty male Sprague-Dawley rats were divided into a normal diet group, low dose group, and high dose group. A non-targeted metabolomics approach was used to compare the metabolic profiles of adipose tissue between the pentosidine and normal diet groups. Furthermore, histopathological observation and body weight change analysis were performed to test the results of the metabolomics analysis. Results: A total of forty-two differential metabolites were identified. Pentosidine mainly disturbed twelve metabolic pathways, such as ascorbate and aldarate metabolism, glycine, serine, and threonine metabolism, sulfur metabolism, pyruvate metabolism, etc. Additionally, pyruvic acid was identified as a possible key upregulated metabolite involved in thirty-four metabolic pathways. α -Ketoglutaric acid was named as a probable key downregulated metabolite involved in nineteen metabolic pathways based on enrichment network analysis. In addition, histopathological analysis and body weight changes confirmed the results of the metabolomics analysis. Conclusions: These results provided a new perspective for the molecular mechanisms of adipose tissue toxicity induced by pentosidine.

Keywords: food safety; mass spectrometry; metabolomics; pentosidine; untargeted metabolite profiling

1. Introduction

Pentosidine is an advanced glycation end product (AGE). It is commonly found in heat-processed foods, particularly under thermal processing at 80–100 °C. It is produced by the Maillard reaction, in which reducing sugars react with free amino groups in proteins or nucleic acids in food [1,2]. The Maillard reaction is a non-enzymatic glycation reaction, which is not only related to the sensory characteristics of food but also closely linked to human health [3]. Dietary habits have changed a lot because of urbanization and globalization. One notable phenomenon is the globally popular western-style fast food, known for its fried and baked foods, with its prevalence steadily increasing [4]. A lot of pentosidine is produced in these foods during high-temperature processing. It was reported that the pentosidine content in baked beef could reach up to $672 \mu g/100 g$. Therefore, dietary intake has become a main source of human exposure to pentosidine [5].

It was reported that the prolonged consumption of foods rich in pentosidine may increase endogenous pentosidine levels [1], induce chronic inflammation and oxidative stress [6], and impair the function of the liver and kidneys [7]. In addition, pentosidine exposure was closely correlated with increased risks of diabetes [8], atherosclerosis [9], and



Citation: Hu, C.; Shao, Z.; Wu, W.; Wang, J. Untargeted Metabolite Profiling Reveals Acute Toxicity of Pentosidine on Adipose Tissue of Rats. *Metabolites* **2024**, *14*, 539. https:// doi.org/10.3390/metabo14100539

Academic Editors: Yasuhiro Date and Eiichiro Fukusaki

Received: 27 August 2024 Revised: 26 September 2024 Accepted: 6 October 2024 Published: 9 October 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). other cardiovascular diseases [10]. Currently, many studies are on the formation mechanism, detection methods, and inhibition strategies of pentosidine. Grandhee and Monnier studied the formation mechanism of pentosidine in reactions involving ribose, lysine, and arginine [11]. Peiretti established an HPLC/MS method for quantifying pentosidine. It facilitated the detection of pentosidine in steaks and other food items [12]. Navarro et al. revealed that hydroxytyrosol, quercetin, gallic acid, and olive leaf extracts were able to efficiently hinder the formation of pentosidine in cookies by inhibiting Amadori product formation, an intermediate in the Maillard reaction [13].

Metabolomic technology based on mass spectrometry (MS), which detects changes in small molecules and obtains a lot of information about metabolic pathways, captures the final dynamic alteration of metabolites in reply to external stressors [14]. The technique has been used to explore the biological effects of food contaminants in organisms. Wu et al. demonstrated that a high level of AGEs in a diet hinders carbohydrate catabolism and helps lipid synthesis with metabolomics. In addition, a high level of AGEs in a diet changes gut microbiota composition and indirectly influences carbohydrate metabolism by the changing levels of glyceraldehyde and pyruvate in plasma [15]. Hu et al. used metabolomics to study potential biomarkers and metabolic pathways in the adipose tissue of rats with mepiquat exposure [16]. Adipose tissue acts as an energy reservoir for lipids, an important regulator of glucose homeostasis and an energetic endocrine organ [17]. Disrupted metabolic states are the key features of adipose tissue of pentosidine-exposed rats by metabolomics.

In the study, non-targeted metabolomics was used to analyze the molecular mechanism of the adipose tissue toxicity of pentosidine. The aim of the study is to test the acute toxicity of pentosidine on the adipose tissue of rats. Firstly, an untargeted metabolomics approach was used to analyze the metabolic changes in adipose tissue in pentosidineexposed rats. Differential metabolites and metabolic networks were identified. Secondly, histopathological observation and body weight changes analysis were performed to test the results of the metabolomics analysis. This study provided new insights into the molecular mechanisms of adipose tissue toxicity induced by pentosidine.

2. Materials and Methods

2.1. Chemical and Reagents

Pentosidine (purity > 98%) was obtained from Cayman Chemical (Ann Arbor, MI, USA). HPLC-grade methanol was provided by Fisher (Fair Lawn, NJ, USA). Standard compounds, 4-chloro-DL-phenylalanine, and derivatization reagent (99%MSTFA + 1%TMCS, pyridine and methoxyamine) were bought at Sigma-Aldrich (St. Louis, MO, USA). Ultrapure water was produced by Milli-Q water system (Millipore Corp., Billerica, MA, USA). All other chemicals were analytical grade.

2.2. Animals and Sample Collection

Male Sprague-Dawley rats aged 5–6 weeks were kept in specific pathogen-free conditions of Department of Laboratory Animal Science of Peking University (Beijing, China). Rats were kept on 12 h light/dark cycle with unrestricted access to water and food. The environmental conditions were maintained at a temperature of 21–23 °C and a humidity of 55–65%. All experimental procedures were conducted in accordance with the European Community guidelines for experimental animal use. All animal experimental plans were agreed by Animal Care and Use Committee of Peking University (approval no. LA2019032).

Thirty rats were randomly divided into three groups of ten rats per group. Rats in the low dose (LD) group and high dose (HD) group were injected with pentosidine solution at concentrations of 0.15 mg/kg/d and 1.5 mg/kg/d via the tail vein, respectively. Rats in the normal diet (ND) group were given 0.5 mL normal saline by the same route. Rats were treated continuously for 3 days. Body weights of rats were recorded every day. On the 4th day, all rats were sacrificed. Epididymal adipose tissues were rapidly collected. Some of them were used for metabolomic analysis. The rest were kept for histopathological analysis.

2.3. Metabolite Extraction of Adipose Tissue

Endogenous metabolite extraction was performed by the method used in previous research [16]. The adipose tissue (0.05 g) was homogenized in 2.0 mL chloroform/methanol solution (v:v, 2:1). The supernatant was collected after centrifugation (9168× g, 4 °C, 5 min). The residue was extracted twice by the same procedure. The combined supernatant was centrifuged (13,201× g, 4 °C, 10 min) and dried with nitrogen. An amount of 15 μ L 4-chloro-DL-phenylalanine (1.05 mg/mL) was added to every sample. Every sample was taken for freeze-drying for 24 h. Then, it was derivatized with MSTFA (0.1 mL) at 70 °C for 3 h [19]. After adding 170 μ L chloroform, each sample was vortexed for 1.0 min and centrifuged (15,493× g, 4 °C, 15 min). The supernatant (0.1 mL) was used for GC-MS analysis. Quality control (QC) samples were prepared by mixing equal volumes (10 μ L) of every sample. QC samples were analyzed once every six samples. They were used to monitor instrument stability and reproducibility [20].

2.4. GC-MS Analysis

Metabolic profiling analysis of adipose tissue was performed using an Agilent 7890A gas chromatograph linked with a 5975C mass spectrometer with an HP-5 MS capillary column (30 m × 250 µm i.d., 0.25 µm). Helium (chromatographic grade) served as the carrier gas with a stable flow rate of 1.0 mL/min. Temperature program was designed as follows: the original temperature was 80 °C and held for 2 min, raised to 180 °C at a rate of 5 °C/min, maintained for 5 min, elevated to 250 °C at a rate of 5 °C/min, held for 5 min, elevated to 250 °C at a rate of 5 °C/min, held for 5 min, then raised to 280 °C at a rate of 8 °C/min, maintained for 2 min. The injector temperature was 280 °C. Auxiliary heating was set at 280 °C. Injection volume was 1 µL. Solvent delay was 5 min. Splitless injection mode was used in analysis. Electron energy was 70 eV. Mass data were obtained in full scan mode covering a mass range of 50–650 m/z. Compound identification was finished by standards and the NIST database (2014) (Gaithersburg, MD, USA).

2.5. Statistical Analysis

Metabolomics data analysis was finished based on previous research [16]. Normalized data were input into SIMCA 14.1 software (Umetrics, Umeå, Sweden) and analyzed by partial least-squares discriminant analysis (PLS-DA) and principal components analysis (PCA) models. Mann–Whitney U test from SPSS 22.0 (SPSS Inc., Chicago, IL, USA) provided *p*-values. Differential metabolites were screened according to variable importance in projection (VIP) (VIP > 1) and *p*-values (p < 0.05). Boxplots were obtained by Origin2021 (OriginLab, Northampton, MA, USA). Metabolic pathway analysis was completed by Metaboanalyst 5.0 website (https://www.metaboanalyst.ca/ (accessed on 2 August 2023)) and Cytoscape v3.7.2 software. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Adobe Illustrator 2023 software were used for analyzing the disrupted metabolic pathways in rats with pentosidine exposure.

2.6. Receiver Operating Characteristic (ROC) Curve Analysis

The area under the ROC curve (AUC) was calculated using SPSS 22.0 software. It was used to assess the ability of differential metabolites to distinguish pentosidine exposure groups from normal diet group. AUC values from 0.5 to 1.0 showed discrimination accuracy. AUC values above 0.8 revealed high discriminatory ability of differential metabolites.

2.7. Histopathological Analysis

Adipose tissues of rats were kept in 10% neutral formalin and processed for paraffin embedding. Samples 5 μ m thick were cut and mounted on slides. These slices were stained by hematoxylin and eosin (H&E) for histological analysis.

3. Results and Discussion

3.1. Weight Change

Compared to the ND group, the body weight changes decreased in rats from the pentosidine-exposed groups. It showed a dose-dependent effect. It suggested that pentosidine significantly inhibited the body weight gain of the rats (p < 0.05), as shown in Figure 1.



Figure 1. Weight changes in rats in ND, LD, and HD groups. Data were expressed as mean \pm standard deviation (SD). Differences in different groups were evaluated by *t*-test, "*" represents p < 0.05, "**" represents p < 0.01. ND group: normal diet group, n = 10; LD group: low dose group, n = 10; HD group: high dose group, n = 10.

3.2. Histopathological Analysis

Adipose tissue samples of rats were analyzed histopathologically. As shown in Figure 2, the adipocytes in the ND group were arranged neatly and closely, with regular size and clear cell contours. It exhibited different sizes and irregular alterations in cells in the LD group. Cell membranes appeared to collapse. In the HD group, there were remarkable changes in the size and shape in the adipocytes, with some cells significantly larger than those in the ND group. Additionally, the contours of cells in the HD group were distorted and blurred. It showed damaged cell membranes. Inflammatory cell infiltration was found. Based on histological alternations, it can be concluded that pentosidine exhibited toxicity in the adipose tissue of rats. The study was to comprehend the pentosidine effects on adipose tissue at the molecular level. Therefore, metabolomics was conducted to investigate how pentosidine influenced the adipose tissue.



Figure 2. Cont.



Figure 2. H&E staining images of adipose tissue from ND, LD, and HD groups (original magnification: $400 \times$). Black arrows: damaged cell membranes; barred arrows: distorted cell contours; doubleheaded arrows: blurred cell contours; dashed arrows: inflammatory cell. ND: normal diet group; LD: low dose group; HD: high dose group.

3.3. GC-MS Analysis of Adipose Tissue

Differential metabolites were screened based on VIP > 1 from the multivariate analysis and p < 0.05 from the Mann–Whitney U test. A total of forty-two differential metabolites in the adipose tissue were quantified by normalization to internal standard (4-chloro-DLphenylalanine). The relative levels of metabolites were presented as fold changes (FC). Compared to the ND group, sixteen upregulated metabolites were identified in the HD group, including glycine, pyrimidine, L-threonine, L-homoserine, 2,5-cyclohexadiene-1,4dione, anthracene, acetic acid, glutamine, pyruvic acid, D-ribose, iron, glutaconic acid, cis-9hexadecenoic acid, hexadecanoic acid, inositol, and eicosapentaenoic acid, while twenty-six downregulated metabolites were identified in the HD group, including ribitol, L-leucine, L-serine, cyclohexanecarboxylic acid, fumaric acid, α -ketoglutaric acid, 2-oxovaleric acid, malonic acid, L-methionine, heptadecane, 2-ketoisocaproic acid, D-glucuronic acid, propionic acid, estrone, sulfurous acid, caprylic acid, naphthalene, butyric acid, benzoic acid, 1,2-benzenedicarboxylic acid, L-ascorbic acid, octadecanoic acid, petroselinic acid, myristic acid, cholesterol, and adipic acid (Table 1). These differential metabolites mainly belong to amino acids, fatty acids, carbohydrates, carboxylic acids, steroids, ketones and their derivatives, as well as benzoic acid and its derivatives, with fatty acids being the most prevalent, followed by amino acids, carboxylic acids, and carbohydrates. In short, our findings indicated that pentosidine acute exposure substantially changed the levels of metabolites in adipose tissue.

3.4. Metabolomics Analysis

PCA and PLS-DA score plots are shown in Figure 3. The close aggregation of QC samples in PCA and PLS-DA models revealed the reliability and stability of metabolomics data. In Figure 3A, it shows that samples of the ND, LD, and HD groups were significantly separated. The parameters were $R^2X = 74.2\%$ and $Q^2 = 49.9\%$, indicating the good quality and predictive ability of the PCA model. It suggested that pentosidine exposure has a remarkable impact on metabolic profiles in adipose tissue.

PLS-DA model was established to assess the metabolic patterns altered by pentosidine. It can better distinguish differences among the three groups. The 999-time permutation tests were utilized to verify the accuracy and predictive ability of the model. As depicted in Figure 3C, the permuted R²Y value was <0.4, and the Q²Y value was <0.05. Therefore, the permutation test indicated that the PLS-DA model was not overfitted. Clear separation among the ND, LD, and HD groups and great parameters (R²X = 81.9%, R²Y = 99.4%, Q² = 92.8%) of the PLS-DA model suggest remarkable metabolic changes induced by pentosidine in a dose-dependent manner (Figure 3B).

Metabolite

Glycine

Ribitol

RT¹ (min)

7.4

10.4

p-Value

 $2.39 imes10^{-4}$

 $3.28 imes 10^{-3}$

No.

1

2

VIP	FC ² (HD-ND)	FDR ³	Trend ⁴	Class ⁵	Metabolic Pathways	
1.06	2.10	$1.0 imes10^{-2}$	1	Amino acids, peptides, and analogues	Glycine, serine, and threonine metabolism	
1.08	0.40	$4.59 imes10^{-3}$	\downarrow	Carbohydrates and carbohydrate conjugates	Pentose and glucuronate interconversions	
1.02	0.56	$1.71 imes 10^{-3}$	\downarrow	Amino acids, peptides, and analogues	Valine, leucine, and isoleucine biosynthesis	
1.18	2.51	$5.02 imes 10^{-3}$	1	Pyrimidines and pyrimidine derivatives	Pyrimidine metabolism	
1.03	0.60	$1.69 imes10^{-3}$	\downarrow	Amino acids, peptides, and analogues	Glycine, serine, and threonine metabolism	
1.06	0.46	$5.44 imes 10^{-3}$	\downarrow	Carboxylic acids	Benzoate degradation	
1.24	0.47	$1.14 imes 10^{-2}$	\downarrow	Dicarboxylic acids and derivatives	TCA cycle	
1.05	1.66	$4.46 imes10^{-3}$	1	Amino acids, peptides, and analogues	Glycine, serine, and threonine metabolism	
1.10	0.24	$2.28 imes 10^{-3}$	\downarrow	Gamma-keto acids and derivatives	TCA cycle	
1.05	0.47	$8.37 imes 10^{-3}$	\downarrow	Short-chain keto acids and derivatives	Lipid metabolism	
1.21	5.58	$1.57 imes 10^{-3}$	¢	Amino acids, peptides, and analogues	Glycine, serine, and threonine metabolism	
1.23	3.21	$2.06 imes 10^{-2}$	¢	Carbonyl compounds Aminobenz oate degrad		
1.04	0.53	2.32×10^{-3}	.l.	Dicarboxylic acids and derivatives	Fatty acid metabolism	

Table 1. Differential metabolites detected in	igh dose group compare	d to normal diet group	by metabolomic anal	vsis based on GC-MS
---	------------------------	------------------------	---------------------	---------------------

4Pyrimidine12.5 2.39×10^{-4} 1.18 2.51 5.02×10^{-3} \uparrow Pyrimidines and pyrimidine derivativesPyrimidine metabolism5L-Serine13.4 6.05×10^{-4} 1.030.60 1.69×10^{-3} \downarrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolis6Cyclohexanecarboxylic acid13.5 4.28×10^{-3} 1.060.46 5.44×10^{-3} \downarrow Carboxylic acidsBenzoate degradation7Fumaric acid13.9 1.08×10^{-2} 1.240.47 1.14×10^{-2} \downarrow Dicarboxylic acids and derivativesTCA cycle8L-Threonine14.1 3.29×10^{-3} 1.051.66 4.46×10^{-3} \uparrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolis9 α -Ketoglutaric acid14.2 1.19×10^{-3} 1.100.24 2.28×10^{-3} \downarrow Gamma-keto acids and derivativesTCA cycle102-Oxovaleric acid14.9 7.37×10^{-3} 1.050.47 8.37×10^{-3} \downarrow Short-chain keto acids and derivativesLipid metabolism11L-Homoserine15.5 6.36×10^{-4} 1.21 5.58 1.57×10^{-3} \uparrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolism12 2.5 -Cyclohexadiene-1,4-dione16.0 2.01×10^{-2} 1.23 3.21 2.06×10^{-2} \uparrow Carbonyl compoundsAminobenz oate degradation13Malonic acid16.1<	
5L-Serine13.4 6.05×10^{-4} 1.030.60 1.69×10^{-3} \downarrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolis6Cyclohexanecarboxylic acid13.5 4.28×10^{-3} 1.060.46 5.44×10^{-3} \downarrow Carboxylic acidsBenzoate degradation7Fumaric acid13.9 1.08×10^{-2} 1.240.47 1.14×10^{-2} \downarrow Dicarboxylic acids and derivativesTCA cycle8L-Threonine14.1 3.29×10^{-3} 1.051.66 4.46×10^{-3} \uparrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolis9 α -Ketoglutaric acid14.2 1.19×10^{-3} 1.000.24 2.28×10^{-3} \downarrow Gamma-keto acids and derivativesTCA cycle102-Oxovaleric acid14.9 7.37×10^{-3} 1.050.47 8.37×10^{-3} \downarrow Short-chain keto acids and derivativesLipid metabolism11L-Homoserine15.5 6.36×10^{-4} 1.21 5.58 1.57×10^{-3} \uparrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolis12 2.5 -Cyclohexadiene-1,4-dione16.0 2.01×10^{-2} 1.23 3.21 2.06×10^{-2} \uparrow Carbonyl compoundsAminobenz oate degradation13Malonic acid16.1 1.38×10^{-3} 1.04 0.53 2.32×10^{-3} \downarrow Dicarboxylic acids and derivativesFatty acid metabolism14L-Methionine16.2	
6Cyclohexanecarboxylic acid13.5 4.28×10^{-3} 1.06 0.46 5.44×10^{-3} \downarrow Carboxylic acidsBenzoate degradation7Fumaric acid13.9 1.08×10^{-2} 1.24 0.47 1.14×10^{-2} \downarrow Dicarboxylic acids and derivativesTCA cycle8L-Threonine14.1 3.29×10^{-3} 1.05 1.66 4.46×10^{-3} \uparrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolis9 α -Ketoglutaric acid14.2 1.19×10^{-3} 1.00 0.24 2.28×10^{-3} \downarrow Gamma-keto acids and derivativesTCA cycle102-Oxovaleric acid14.9 7.37×10^{-3} 1.05 0.47 8.37×10^{-3} \downarrow Short-chain keto acids and derivativesLipid metabolism11L-Homoserine15.5 6.36×10^{-4} 1.21 5.58 1.57×10^{-3} \uparrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolis12 2.5 -Cyclohexadiene-1,4-dione 16.0 2.01×10^{-2} 1.23 3.21 2.06×10^{-2} \uparrow Carboxylic acids and derivativesFatty acid metabolism13Malonic acid 16.1 1.38×10^{-3} 1.04 0.53 2.32×10^{-3} \downarrow Dicarboxylic acids and derivativesFatty acid metabolism14L-Methionine 16.2 1.75×10^{-3} 1.12 0.38 2.82×10^{-3} \downarrow AlkanesLipid metabolism15Heptadecane 16.6 3.79	lism
7Fumaric acid 13.9 1.08×10^{-2} 1.24 0.47 1.14×10^{-2} \downarrow Dicarboxylic acids and derivativesTCA cycle8L-Threonine 14.1 3.29×10^{-3} 1.05 1.66 4.46×10^{-3} \uparrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolis9 α -Ketoglutaric acid 14.2 1.19×10^{-3} 1.10 0.24 2.28×10^{-3} \downarrow Gamma-keto acids and derivativesTCA cycle10 2 -Oxovaleric acid 14.9 7.37×10^{-3} 1.05 0.47 8.37×10^{-3} \downarrow Short-chain keto acids and derivativesLipid metabolism11L-Homoserine 15.5 6.36×10^{-4} 1.21 5.58 1.57×10^{-3} \uparrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolis12 $2,5$ -Cyclohexadiene- $1,4$ -dione 16.0 2.01×10^{-2} 1.23 3.21 2.06×10^{-2} \uparrow Carbonyl compoundsAminobenz oate degradation13Malonic acid 16.1 1.38×10^{-3} 1.04 0.53 2.32×10^{-3} \downarrow Dicarboxylic acids and derivativesFatty acid metabolism14L-Methionine 16.2 1.75×10^{-3} 1.12 0.38 2.82×10^{-3} \downarrow Amino acids, peptides, and analoguesCysteine and methionine metabolism15Heptadecane 16.6 3.79×10^{-4} 1.11 0.29 1.22×10^{-3} \downarrow AlkanesLipid metabolism16 2 -Ketoiso	
8L-Threonine14.1 3.29×10^{-3} 1.051.66 4.46×10^{-3} \uparrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolities9 α -Ketoglutaric acid14.2 1.19×10^{-3} 1.10 0.24 2.28×10^{-3} \downarrow Gamma-keto acids and derivativesTCA cycle102-Oxovaleric acid14.9 7.37×10^{-3} 1.05 0.47 8.37×10^{-3} \downarrow Short-chain keto acids and derivativesLipid metabolism11L-Homoserine15.5 6.36×10^{-4} 1.21 5.58 1.57×10^{-3} \uparrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolis12 2.5 -Cyclohexadiene-1,4-dione16.0 2.01×10^{-2} 1.23 3.21 2.06×10^{-2} \uparrow Carbonyl compoundsAminobenz cate degradation13Malonic acid16.1 1.38×10^{-3} 1.12 0.38 2.82×10^{-3} \downarrow Amino acids, peptides, and analoguesCysteine and methionine metabolism14L-Methionine16.2 1.75×10^{-3} 1.12 0.38 2.82×10^{-3} \downarrow Amino acids, peptides, and analoguesCysteine and methionine metabolism15Heptadecane16.6 3.79×10^{-4} 1.11 0.29 1.22×10^{-3} \downarrow Amino acids, peptides, and analoguesCysteine and methionine metabolism16 2 -Ketoisocaproic acid16.9 2.39×10^{-4} 1.01 0.33 3.35×10^{-3} \downarrow Short-chain keto acids and derivativesValine, le	
9 α -Ketoglutaric acid14.2 1.19×10^{-3} 1.10 0.24 2.28×10^{-3} \downarrow Gamma-keto acids and derivativesTCA cycle102-Oxovaleric acid14.9 7.37×10^{-3} 1.05 0.47 8.37×10^{-3} \downarrow Short-chain keto acids and derivativesLipid metabolism11L-Homoserine15.5 6.36×10^{-4} 1.21 5.58 1.57×10^{-3} \uparrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolis12 $2,5$ -Cyclohexadiene-1,4-dione16.0 2.01×10^{-2} 1.23 3.21 2.06×10^{-2} \uparrow Carbonyl compoundsAminobenz oate degradation13Malonic acid16.1 1.38×10^{-3} 1.04 0.53 2.32×10^{-3} \downarrow Dicarboxylic acids and derivativesFatty acid metabolism14L-Methionine 16.2 1.75×10^{-3} 1.12 0.38 2.82×10^{-3} \downarrow Amino acids, peptides, and analoguesCysteine and methionine metabolism15Heptadecane 16.6 3.79×10^{-4} 1.11 0.29 1.22×10^{-3} \downarrow AlkanesLipid metabolism16 2 -Ketoisocaproic acid 16.9 2.39×10^{-4} 1.01 0.33 3.35×10^{-3} \downarrow Short-chain keto acids and derivativesValine, leucine, and isoleucine biosynthe	olism
102-Oxovaleric acid14.9 7.37×10^{-3} 1.05 0.47 8.37×10^{-3} \downarrow Short-chain keto acids and derivativesLipid metabolism11L-Homoserine15.5 6.36×10^{-4} 1.215.58 1.57×10^{-3} \uparrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolism12 $2,5$ -Cyclohexadiene-1,4-dione16.0 2.01×10^{-2} 1.23 3.21 2.06×10^{-2} \uparrow Carbonyl compoundsAminobenz oate degradation13Malonic acid16.1 1.38×10^{-3} 1.04 0.53 2.32×10^{-3} \downarrow Dicarboxylic acids and derivativesFatty acid metabolism14L-Methionine16.2 1.75×10^{-3} 1.12 0.38 2.82×10^{-3} \downarrow Amino acids, peptides, and analoguesCysteine and methionine metabolism15Heptadecane16.6 3.79×10^{-4} 1.11 0.29 1.22×10^{-3} \downarrow AlkanesLipid metabolism16 2.49×10^{-4} 1.01 0.33 3.35×10^{-3} \downarrow Short-chain keto acids and derivativesValine, leucine, and isoleucine biosynthe	
11L-Homoserine15.5 6.36×10^{-4} 1.21 5.58 1.57×10^{-3} \uparrow Amino acids, peptides, and analoguesGlycine, serine, and threonine metabolis12 $2,5$ -Cyclohexadiene-1,4-dione 16.0 2.01×10^{-2} 1.23 3.21 2.06×10^{-2} \uparrow Carbonyl compoundsAminobenz oate degradation13Malonic acid 16.1 1.38×10^{-3} 1.04 0.53 2.32×10^{-3} \downarrow Dicarboxylic acids and derivativesFatty acid metabolism14L-Methionine 16.2 1.75×10^{-3} 1.12 0.38 2.82×10^{-3} \downarrow Amino acids, peptides, and analoguesCysteine and methionine metabolism15Heptadecane 16.6 3.79×10^{-4} 1.11 0.29 1.22×10^{-3} \downarrow AlkanesLipid metabolism16 2 -Ketoisocaproic acid 16.9 2.39×10^{-4} 1.01 0.33 3.35×10^{-3} \downarrow Short-chain keto acids and derivativesValine, leucine, and isoleucine biosynthe	
122,5-Cyclohexadiene-1,4-dione16.0 2.01×10^{-2} 1.23 3.21 2.06×10^{-2} \uparrow Carbonyl compoundsAminobenz oate degradation13Malonic acid16.1 1.38×10^{-3} 1.04 0.53 2.32×10^{-3} \downarrow Dicarboxylic acids and derivativesFatty acid metabolism14L-Methionine16.2 1.75×10^{-3} 1.12 0.38 2.82×10^{-3} \downarrow Amino acids, peptides, and analoguesCysteine and methionine metabolism15Heptadecane16.6 3.79×10^{-4} 1.11 0.29 1.22×10^{-3} \downarrow AlkanesLipid metabolism16 2.48×10^{-4} 1.01 0.33 3.35×10^{-3} \downarrow Short-chain keto acids and derivativesValine, leucine, and isoleucine biosynthe	lism
13Malonic acid16.1 1.38×10^{-3} 1.04 0.53 2.32×10^{-3} \downarrow Dicarboxylic acids and derivativesFatty acid metabolism14L-Methionine16.2 1.75×10^{-3} 1.12 0.38 2.82×10^{-3} \downarrow Amino acids, peptides, and analoguesCysteine and methionine metabolism15Heptadecane16.6 3.79×10^{-4} 1.11 0.29 1.22×10^{-3} \downarrow AlkanesLipid metabolism16 2.49×10^{-4} 1.01 0.33 3.35×10^{-3} \downarrow Short-chain keto acids and derivativesValine, leucine, and isoleucine biosynthe	
14L-Methionine16.2 1.75×10^{-3} 1.12 0.38 2.82×10^{-3} \downarrow Amino acids, peptides, and analoguesCysteine and methionine metabolism15Heptadecane16.6 3.79×10^{-4} 1.11 0.29 1.22×10^{-3} \downarrow AlkanesLipid metabolism16 2.46×10^{-3} 1.01 0.33 3.35×10^{-3} \downarrow Short-chain keto acids and derivativesValine, leucine, and isoleucine biosynthe	
	m
16 2-Ketoisocaproic acid 16.9 2.39×10^{-4} 1.01 0.33 3.35×10^{-3} \downarrow Short-chain keto acids and derivatives Valine, leucine, and isoleucine biosynthetic derivatives Valine, leucine, and leucine,	
	hesis
17 D-Glucuronic acid 17.5 3.79×10^{-4} 1.03 0.38 1.14×10^{-3} \downarrow Carbohydrates and carbohydrate conjugates Amino sugar and nucleotide sugar metabolic sugar metaboli	bolism
18Propionic acid17.9 5.50×10^{-3} 1.03 0.54 6.60×10^{-3} \downarrow Carboxylic acidsPropanoate metabolism	
19Anthracene18.8 6.36×10^{-4} 1.357.92 1.48×10^{-3} \uparrow AnthracenesPolycyclic aromatic hydrocarbon degrada	dation
20 Acetic acid 18.9 7.69×10^{-3} 1.09 1.90 8.50×10^{-3} \uparrow Carboxylic acids and derivatives Glycolysis/gluconeogenesis	
21 Estrone 19.3 8.48×10^{-3} 1.09 0.12 1.70×10^{-3} \downarrow Estrone steroids Steroid hormone biosynthesis	
22 Glutamine 19.7 6.36×10^{-4} 1.07 3.93 4.41×10^{-3} \uparrow Amino acids, peptides, and analogues Alanine, aspartate, and glutamate metabolic for the second	bolism
23 Pyruvic acid 20.0 2.39×10^{-4} 1.03 2.54 2.51×10^{-3} \uparrow Alpha-keto acids and derivatives TCA cycle	
24 D-Ribose 20.6 2.39×10^{-4} 1.31 3.59 2.01×10^{-3} \uparrow Carbohydrates and carbohydrate conjugates Pentose phosphate pathway	
25 Iron 21.1 2.39×10^{-4} 1.07 2.86 1.67×10^{-3} \uparrow Homogeneous transition metal compounds Porphyrin metabolism	
26Sulfurous acid21.3 1.79×10^{-3} 1.01 0.54 2.79×10^{-3} \downarrow Non-metal sulfitesCysteine and methionine metabolism	m
27Caprylic acid21.8 2.66×10^{-3} 1.01 0.26 3.86×10^{-3} \downarrow Fatty acids and conjugatesFatty acid biosynthesis	
28Naphthalene22.1 3.49×10^{-4} 1.08 0.38 1.33×10^{-3} \downarrow NaphthalenesDegradation of aromatic compounds	ds
29 Butyric acid 22.8 1.06×10^{-2} 1.26 0.53 1.14×10^{-2} \downarrow Fatty acids and conjugates Butanoate metabolism	
30 Glutaconic acid 22.9 1.19×10^{-3} 1.43 5.134 2.18×10^{-3} \uparrow Dicarboxylic acids and derivatives Fatty acid metabolism	
31 Benzoic acid 27.3 2.39×10^{-4} 1.07 0.50 1.43×10^{-3} \downarrow Benzoic acids and derivatives Benzoate degradation	

Table 1. Cont.

No.	Metabolite	RT ¹ (min)	<i>p</i> -Value	VIP	FC ² (HD-ND)	FDR ³	Trend ⁴	Class ⁵	Metabolic Pathways
32	1,2-Benzenedicarboxylic acid	28.2	$3.37 imes10^{-3}$	2.24	0.38	$4.42 imes 10^{-3}$	\downarrow	Benzoic acids and derivatives	Polycyclic aromatic hydrocarbon degradation
33	L-Ascorbic acid	29.9	$5.48 imes10^{-3}$	1.82	0.26	$6.77 imes 10^{-3}$	\downarrow	Furanones	Ascorbate and aldarate metabolism
34	Cis-9-Hexadecenoic acid	30.6	$1.37 imes 10^{-3}$	1.27	2.09	$2.40 imes10^{-3}$	1	Fatty acids and conjugates	Fatty acid biosynthesis
35	Hexadecanoic acid	31.6	$4.12 imes 10^{-2}$	1.05	1.27	$4.12 imes 10^{-2}$	1	Fatty acids and conjugates	Fatty acid biosynthesis
36	Inositol	33.0	$3.49 imes10^{-4}$	1.03	2.08	$1.22 imes 10^{-3}$	1	Alcohols and polyols	Inositol phosphate metabolism
37	Octadecanoic acid	35.6	$1.92 imes 10^{-3}$	1.04	0.56	$2.88 imes10^{-3}$	\downarrow	Fatty acids and conjugates	Biosynthesis of unsaturated fatty acids
38	Eicosapentaenoic acid	38.3	$2.39 imes10^{-3}$	1.31	3.02	$1.25 imes 10^{-3}$	↑	Fatty acids and conjugates	Biosynthesis of unsaturated fatty acids
39	Petroselinic acid	38.8	$6.05 imes10^{-4}$	1.10	0.28	$1.59 imes10^{-3}$	\downarrow	Fatty acids and conjugates	Biosynthesis of unsaturated fatty acids
40	Myristic acid	39.0	$2.39 imes10^{-4}$	1.25	0.32	$1.11 imes 10^{-3}$	\downarrow	Fatty acids and conjugates	Fatty acid biosynthesis
41	Cholesterol	42.0	$2.39 imes10^{-4}$	1.07	0.34	$1.00 imes 10^{-3}$	\downarrow	Cholestane steroids	Cholesterol metabolism
42	Adipic acid	42.8	$7.05 imes 10^{-3}$	1.04	0.50	$8.23 imes 10^{-3}$	\downarrow	Fatty acids and conjugates	Degradation of aromatic compounds

¹ RT: retention time. ² FC: fold change. It represents the ratio of peak intensity of high dose group to normal diet group. ³ FDR: false discovery rate. ⁴ Trend: "↑" represents an increase in differential metabolites in high dose group compared to normal diet group; "↓" means a decrease in differential metabolites in high dose group compared to normal diet group. ⁵ Class: obtained from Human Metabolome Database (HMDB).



Figure 3. Multivariate statistical analysis of results from GC–MS analysis. (**A**) PCA score plot analysis ($R^2X = 74.2\%$, $Q^2 = 49.9\%$); (**B**) PLS–DA score plot analysis ($R^2X = 81.9\%$, $R^2Y = 99.4\%$, $Q^2 = 92.8\%$); (**C**) permutation plot for PLS–DA model (n = 999), $R^2 = (0.0, 0.253)$, $Q^2 = (0.0, -0.177)$. PCA: principal component analysis; PLS–DA: partial least squares discriminant analysis; ND: normal diet group, n = 10; LD: low dose group, n = 10; HD: high dose group, n = 10; QC: quality control.

Boxplots were used to show changes in the relative levels of differential metabolites in the HD, LD, and ND groups (Figure 4). Compared to the ND group, the levels of inositol and pyruvic acid increased in the pentosidine-exposed groups. In contrast, the amounts of petroselinic acid and D-glucuronic acid content decreased in the pentosidine-exposed groups. These changes showed a dose-dependent relationship in the three groups.

3.5. ROC Curve

The ability of these differential metabolites to distinguish the normal diet group from the pentosidine-exposed groups was assessed by AUC values. Each differential metabolite was characterized by the AUC value ranging from 0.8 and 1. Thus, forty-two differential metabolites can effectively distinguish rats in the ND group from those in the pentosidineexposed groups (Table S1).



Figure 4. Boxplots of differential metabolites in adipose tissue of rats in ND, LD, and HD groups. Differences in different groups were evaluated by Mann–Whitney U test. "*" means p < 0.05, "**" means p < 0.01, "***" means p < 0.001. ND group: normal diet group, n = 10; LD group: low dose group, n = 10; HD group: high dose group, n = 10.

3.6. Metabolic Pathway Analysis

Forty-two differential metabolites were input into the MetaboAnalyst 5.0 website for pathway analysis. It linked changes in metabolites to metabolic networks. There were twenty-one metabolic pathways enriched in the adipose tissue. Twelve of them were perturbed significantly (the impact threshold sourced from the pathway analysis is above 0.1), such as ascorbate and aldarate metabolism, glycine, serine, and threonine metabolism, sulfur metabolism, pyruvate metabolism, aminoacyl-tRNA biosynthesis, alanine, aspartate and glutamate metabolism, glycxylate and dicarboxylate metabolism, citrate cycle (TCA cycle), glycolysis/gluconeogenesis, inositol phosphate metabolism, cysteine and methionine metabolism, and pentose and glucuronate interconversions (Figure 5 and Table S2). The results exhibited disruptions in carbohydrate metabolism, energy metabolism, amino acid metabolism, and the other metabolic pathways of adipose tissue induced by pentosidine. The most remarkably impacted pathway was ascorbate and aldarate metabolism (Figure S1), a significant carbohydrate metabolic pathway that prevents cells from oxidative damage [21]. In short, this indicated the possible impacts of pentosidine acute exposure on metabolic pathways.



Figure 5. Disturbed pathways in adipose tissue of rats from ND, LD, and HD groups. Node color in pathway analysis represented its *p*-value; node radius reflected their pathway impact values. (1) Ascorbate and aldarate metabolism, (2) glycine, serine, and threonine metabolism, (3) sulfur metabolism, (4) pyruvate metabolism, (5) aminoacyl–tRNA biosynthesis, (6) alanine, aspartate, and glutamate metabolism, (7) glyoxylate and dicarboxylate metabolism, (8) citrate cycle (TCA cycle), (9) glycolysis/gluconeogenesis, (10) inositol phosphate metabolism, (11) cysteine and methionine metabolism, (12) pentose and glucuronate interconversions. ND group: normal diet group, n = 10; LD group: low dose group, n = 10; HD group: high dose group, n = 10.

Based on the chemical structures of metabolites and the functional groups classification from PubChem, MetaMapp was used to form the metabolic network related to differential metabolites. The molecular metabolite network was constructed to obtain an overall view of metabolomics datasets in Cytoscape software (Figure 6). The blue-dotted box revealed amino acid, energy, and fatty acid metabolism. The yellow-dotted box showed carbohydrate metabolism. The green-dotted box was related to nucleotide metabolism and other pathways. The comprehensive metabolic pathway of metabolites in adipose tissue accurately reflected its metabolic state. There were both upregulated and downregulated metabolites among the forty-two differential metabolites. L-Homoserine showed the largest change among upregulated metabolites, while L-serine had the greatest change among downregulated metabolites. It indicated that pathways linked to L-homoserine and Lserine were particularly affected, such as glycine, serine, and threonine metabolism and cysteine and methionine metabolism. It highlighted the influence of pentosidine on amino acid metabolism in adipose tissue. Notably, a series of fatty acids and their derivatives, carbohydrates, carboxylic acids, and steroids displayed significant changes. Pentosidine caused more remarkable disruption in fatty acid metabolism.

As shown in Figure 7, twenty-six downregulated and sixteen upregulated metabolites were significantly altered by pentosidine in adipose tissue. Seventy-two metabolic pathways involving eight routes were impacted (Table S3). Amino acid, carbohydrate, and fatty acid metabolisms were notably affected, especially with downregulation in unsaturated fatty acid biosynthesis and steroid biosynthesis. The dysregulation of pyruvic acid and α -ketoglutaric acid affected thirty-four and nineteen pathways, respectively. Therefore, pyruvic acid was regarded as a possible key upregulated metabolite. α -Ketoglutaric acid was considered as a probable key downregulated metabolite. Based on the KEGG database, an overview of significantly changed metabolites and pathways in the adipose tissue of rats with pentosidine exposure is shown in Figure 8.



Figure 6. Pathway mapping of differential metabolites detected in HD group compared to ND group. Metabolic pathway generated through MetaMapp and drawn by Cytoscape. The depicted network reveals that red nodes represent significantly upregulated metabolites, blue nodes show remarkably downregulated metabolites, and gray nodes reveal no significant changes in metabolites. Size of node is positively correlated with fold change between HD group and ND group. ND group: normal diet group, n = 10; LD group: low dose group, n = 10; HD group: high dose group.



Figure 7. Network analysis of differential metabolites and metabolic pathways in pentosidineexposed groups shows that there are forty-two differential metabolites. "*" represents p < 0.05, "**"

represents p < 0.01, "***" represents p < 0.001. The red circles and black circles show upregulated and downregulated metabolites, respectively. Intensity of colors indicates fold changes in metabolites. A total of seventy-two metabolic pathways are classified as eight metabolic pathways (Table S3) and connected to different metabolites by the red line (upregulated) and black line (downregulated).



Figure 8. Interplay between differential metabolites in HD group compared to ND group. Metabolic pathways are illustrated based on information obtained from KEGG database. Red boxes represent increased metabolites, blue boxes show decreased metabolites, blank boxes reveal no significant changes in metabolites. Numbers 1 to 12 represent metabolic pathways with impact value larger than 0.1 (Figure 5). ND group: normal diet group, n = 10; LD group: low dose group, n = 10; HD group: high dose group, n = 10.

3.7. Metabolic Disturbance of Adipose Tissue after Pentosidine Exposure

Amino acid metabolism plays an essential role in cellular function, such as cellular signaling and protein and lipid synthesis. One of the most remarkably changed pathways between the pentosidine-exposed groups and the ND group was glycine, serine, and threonine metabolism (Figure 5) in this study. It provides nicotinamide adenine dinucleotide phosphate (NADPH) and participates in the TCA cycle, gluconeogenesis, and macromolecular biosynthesis [22]. Serine, glycine, and threonine can be converted to each other by the action of threonine aldolase and serine hydroxymethyltransferase [23]. Glycine serves as an effective nitrogen source and can be converted into pyruvate, subsequently entering the TCA cycle as an amino acid skeleton. It plays crucial roles in metabolic regulation, neurological function, and antioxidant response [24]. It has been shown that L-threonine is required for the inhibition of lipogenesis and the promotion of lipolysis in epididymal adipose tissue [25]. One-carbon units produced by L-serine are crucial for heat generation and ATP in adipose cells [26]. L-serine is a key component in the synthesis of phospholipids, especially phosphatidylserine and sphingolipids, which are highly concentrated in all cellular membranes [27]. Homoserine is a more reactive variant of serine. It is also involved in the metabolism of glycine, serine, and threonine [24]. Therefore, we believed that a significant increase in glycine, L-threonine, and L-homoserine, along with a notable decrease in L-serine, indicated the disruption in glycine, serine, and threonine metabolism, which may result in adipose tissue disorders. Glutamine, a vital non-essential

amino acid, is abundant in the human body. High levels of glutamine can help cancer cell proliferation by acting as carbon and nitrogen sources for fatty acids, nucleotides, and non-essential amino acids synthesis. Glutamine is also included in glutathione and NADPH production. Additionally, it is a potent anaplerotic substrate to maintain the TCA cycle [28,29]. Therefore, the significant increase in glutamine revealed disturbances in glutamate and glutamine pathways. This possibly impacted the TCA cycle. It can be found in a remarkable decrease in α-ketoglutaric acid, an intermediate product of the TCA cycle (Figure 8). Pentosidine exposure also resulted in a significant decrease in L-leucine and 2-ketoisocaproic acid, along with a remarkable increase in glutaconic acid. An intermediate of leucine metabolism, 2-Ketoisocaproic acid, might enter the cellular energy metabolism by 2-keto acid dehydrogenase [30]. Leucine also acts as a regulator of lipid metabolism, helping to reduce obesity and fat accumulation [31]. These changes indicated disorders of energy metabolism and lipid metabolism in adipose tissue. An increase in reactive oxygen species (ROS) in cells in an inflammatory environment will induce the oxidation of sulfur in L-methionine residues, forming L-methionine-S-oxide. It will lower the level of L-methionine. The lack of L-methionine will result in a deficient supply of sulfur in cells. Sulfur is crucial for the formation of iron-sulfur clusters in cells. These clusters can decrease iron accumulation to prevent the occurrence of ferroptosis [32,33]. Additionally, benzoic acid is naturally found in animal tissues. It shows a negative correlation with ROS [34,35]. Therefore, the downregulation of benzoic acid in pentosidine-exposed groups might induce oxidative stress. A decrease in L-methionine and an increase in iron after pentosidine acute exposure suggested that L-methionine may be oxidized to become L-methionine-S-oxide. Pyrimidine is a fundamental constituent of DNA and RNA. Pyrimidine metabolic abnormality disturbed nervous, hematological, or mitochondrial systems [36,37]. Additionally, 2,5-cyclohexadiene-1,4-dione is known to be involved in oxidative stress and DNA damage [38]. The increase in 2,5-cyclohexadiene-1,4-dione in this study indicated its potential harm.

The increase in pyruvic acid, along with the decrease in fumaric acid and α -ketoglutaric acid, was observed (Figure 6) in the pentosidine-exposed groups. They were involved in pyruvate metabolism and the TCA cycle, respectively. The TCA cycle, as the central hub of cellular energy metabolism, coordinates metabolisms of glucose, fatty acids, and amino acids. Metabolites of the TCA cycle also take part in nonenergy production activities, including biosynthesis, maintaining redox homeostasis, and modulating inflammation [39]. Pyruvic acid is a key compound in energy metabolism. It is decarboxylated with pyruvate dehydrogenase complex. It gives an additional NADPH molecule and acetyl-coenzyme A, an entry-level substrate for the TCA cycle [40]. Significant alterations in fumaric acid, α -ketoglutaric acid, and pyruvic acid indicated a negative influence of pentosidine acute exposure on interconnected pathways such as pyruvate metabolism and the TCA cycle. Ribitol, as a reduction product of D-ribose, enhances glycolysis by increasing the production of pyruvic acid and lactic acid [41]. Compared to the ND group, an increase in D-ribose and a decrease in ribitol in pentosidine-exposed groups might disturb ribose metabolism and glycolysis/gluconeogenesis pathways, potentially leading to inflammatory responses [42]. As a precursor of lipids and inositol phosphates, inositol plays a significant biological role in growth regulation, signaling, and membrane lipid synthesis. Moreover, inositol can be converted to D-glucuronic acid and enter the pentose phosphate pathway [43]. D-Glucuronic acid is considered the most powerful detoxifying natural compound in an organism due to its ability to conjugate itself with noxious metabolites or waste products [44]. Additionally, as a component of hyaluronic acid, D-glucuronic acid is implicated in the regulation of the extracellular matrix and inflammatory conditions in adipose tissue [45]. L-Ascorbic acid was shown to inhibit free radical generation and reduce oxidative damage resulting from ROS [46]. Therefore, significant changes in inositol, D-glucuronic acid, and L-ascorbic acid indicated disruptions in inositol phosphate metabolism, pentose and glucuronate interconversions, and ascorbate and aldarate metabolism, revealing the dysfunction of adipose tissue.

In addition to being included in energy metabolism, short-chain fatty acids (SCFAs) can activate G-protein-coupled receptors as signaling molecules [47]. In this study, there was a notable rise in acetic acid, while levels of propionic acid and butyric acid decreased significantly. Propionic acid and butyric acid reduced the total fat mass, subcutaneous fat mass, and macrovesicular steatosis [48,49]. Butyric acid can also help brown–white tissue, decrease the size of adipose cells in morphology, and increase the number of multicellular adipocytes [50]. Notable alterations in the levels of SCFAs may result in fatty acid β -oxidation, inflammation, and insulin resistance [51]. Sulfurous acid is formed by the catabolism of cysteine and methionine. It improves intracellular glutathione to keep neurons from oxidative stress [52]. As shown in Figure 5, the cysteine and methionine metabolism were significantly disturbed in the adipose tissue of rats with pentosidine acute exposure. Therefore, we believed that a decrease in sulfurous acid was in connection with the disruption of cysteine and methionine metabolism. It might lead to imbalances in glutathione biosynthesis and oxidative stress.

The metabolites associated with fatty acid metabolism, such as malonic acid, caprylic acid, octadecanoic acid, and so on, exhibited significant changes in this study. White adipose tissue was widely considered an energy homeostasis center for the lipolysis of fatty acids (FAs) and the lipid storage of the whole body. FAs have many fates including oxidation to generate ATP for energy, reesterification back into triacylglycerols, and also serving as signaling molecules [53]. FAs are also important parts for membrane structure lipids [17]. In addition, excessive FAs released by the adipocyte are regarded as a major contributor to tissue inflammation and can lead to various metabolic diseases [54]. Therefore, changes in FAs indicated a dysregulation in fatty acid metabolism in the adipose tissue of rats with pentosidine acute exposure. Malonic acid plays an important role in fatty acid biosynthesis under the action of malonyl-CoA. Malonyl-CoA is an important intermediate metabolite in fatty acid biosynthesis. It is reversibly changed to malonic acid in cells [55]. Therefore, a decrease in malonic acid caused by pentosidine acute exposure suggested a disruption of fatty acid biosynthesis in the adipose tissue. Since caprylic acid is ketogenic, it could offer an additional source of energy, generally in the form of β -hydroxybutyrate, which aborts impaired glucose metabolism in Alzheimer's disease [56]. Additionally, caprylic acid induced a large reduction in the expression of crucial enzymes in FA uptake and triglyceride synthesis [57]. Therefore, a decrease in caprylic acid might promote triglyceride production, the disorder of lipid metabolism, and insufficient energy supply for patients with Alzheimer's disease. Compared to other saturated fatty acids, octadecanoic acid inhibits cell growth at specific concentrations [58]. In addition, it is also a regulator of mitochondrial function. The loss of octadecanoic acid leads to mitochondrial fragmentation, which will accelerate the production of ROS and apoptosis [59]. Thus, a decrease in octadecanoic acid in this study might seriously interfere with the normal function of adipocytes. It might also increase the production of triglyceride substrates, such as cis-9hexadecenoic acid. High contents of cis-9-hexadecenoic acid quicken fat deposition [60]. Furthermore, pentosidine helped the accumulation of saturated fatty acids, including hexadecanoic acid. It was reported that saturated fatty acids were the major contributors for lipotoxicity by helping oxidative stress and cell apoptosis [61]. Myristic acid performed an anti-inflammatory effect by increasing IL-10. Myristic acid slightly modulated the activity of peroxisome proliferator activated receptor α , a nuclear receptor with a crucial role in the regulation of mitochondrial metabolism and mitochondrial biogenesis [62]. Therefore, a decrease in myristic acid in this study could hinder its vital physiological function in adipose tissue. Petroselinic acid helped improve synthesis and the collection of eicosapentaenoic acid (EPA). EPA stabilized membranes and maintained a normal distribution of membrane cholesterol [63]. It was found that EPA helped ABCA1-mediated cholesterol efflux from macrophages. It was the main mechanism to remove cholesterol from tissues to the liver [64]. These alterations were correlated with an increase in EPA. In this study, changes in petroselinic acid and EPA were consistent with the literature [63]. Cholesterol is a primary components of the cell membrane. It participates in the regulation

of permeability, fluidity of the membrane, and cell signaling [65]. Thus, a decrease in cholesterol and estrone in the study could disrupt cholesterol metabolism and steroid hormone synthesis (Figure 7).

4. Conclusions

It is the first time that an untargeted metabolomics study has been completed to investigate the possible toxic mechanism of pentosidine on adipose tissue. Forty-two differential metabolites were identified. Sixteen metabolites were significantly upregulated. Conversely, twenty-six metabolites were significantly downregulated. The most important upregulated metabolite was possibly pyruvic acid, which was involved in thirty-four metabolic pathways. α -Ketoglutaric acid was a probable key downregulated metabolite involved in nineteen metabolic pathways. Major disturbed pathways, including ascorbate and aldarate metabolism, glycine, serine, and threonine metabolism, sulfur metabolism, pyruvate metabolism, aminoacyl-tRNA biosynthesis, alanine, aspartate, and glutamate metabolism, glyoxylate and dicarboxylate metabolism, TCA cycle, glycolysis/gluconeogenesis, inositol phosphate metabolism, cysteine and methionine metabolism, and pentose and glucuronate interconversions were found based on the pathway analysis. Changes in the levels of amino acids, fatty acids, carbohydrates, and other metabolites and the disturbance of energy metabolism, fatty acid, and amino acid metabolism were found in this study. In addition, the histopathological analysis of adipose tissue and body weight changes confirmed the results of the metabolomics analysis. It may provide a new perspective on the molecular mechanisms of adipose toxicity induced by pentosidine.

Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/metabo14100539/s1, Figure S1: Ascorbate and aldarate metabolic pathway in adipose tissue of rats among different groups; Table S1: Parameters of the receiver operating characteristic curves for differential metabolites; Table S2: Pathway analysis results of differential metabolites with MetaboAnalyst 5.0; Table S3: The list of metabolic pathways.

Author Contributions: Conceptualization, J.W.; formal analysis, C.H. and Z.S.; funding acquisition, C.H. and J.W.; data curation, C.H.; methodology, C.H., Z.S., W.W. and J.W.; resources, J.W.; project administration, J.W.; software, Z.S.; visualization, C.H. and Z.S.; supervision, J.W.; writing—original draft, C.H.; writing—review and editing, J.W. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the National Natural Science Foundation of China (Nos. 31901808, 31972111), and the Project of High-Level Teacher in Beijing Municipal Universities (IDHT20180506).

Institutional Review Board Statement: The animal study procedure was agreed by the Animal Care and Use Committee of Peking University (approval no. LA2019032, approved in December 2019).

Informed Consent Statement: Not applicable.

Data Availability Statement: All data are within the manuscript and Supplementary Materials.

Conflicts of Interest: The authors declare no conflicts of interest.

References

- 1. Li, H.; Yu, S.J. Review of pentosidine and pyrraline in food and chemical models: Formation, potential risks and determination. *J. Sci. Food Agr.* **2018**, *98*, 3225–3233. [CrossRef] [PubMed]
- Deramon, E.A.; Sabbasani, V.R.; Streeter, M.D.; Liu, Y.N.; Newhouse, T.R.; Mcdonald, D.M.; Spiegel, D.A. Pentosinane, a post-translational modification of human proteins with underappreciated stability. *J. Am. Chem. Soc.* 2022, 144, 21843–21847. [CrossRef] [PubMed]
- Cui, H.P.; Yu, J.H.; Zhai, Y.; Feng, L.H.; Chen, P.S.; Hayat, K.; Xu, Y.; Zhang, X.M.; Ho, C.T. Formation and fate of Amadori rearrangement products in Maillard reaction. *Trends Food Sci. Tech.* 2021, 115, 391–408. [CrossRef]
- Qu, W.; Nie, C.; Zhao, J.; Ou, X.; Zhang, Y.; Yang, S.; Bai, X.; Wang, Y.; Wang, J.; Li, J. Microbionne-metabolomics analysis of the impacts of long-term dietary advanced-glycation-end-product consumption on C57BL/6 mouse fecal microbiota and metabolites. J. Agric. Food Chem. 2018, 66, 8864–8875. [CrossRef] [PubMed]

- Chao, P.C.; Hsu, C.C.; Yin, M.C. Analysis of glycative products in sauces and sauce-treated foods. *Food Chem.* 2009, 113, 262–266. [CrossRef]
- Ott, C.; Jacobs, K.; Haucke, E.; Santos, A.N.; Grune, T.; Simm, A. Role of advanced glycation end products in cellular signaling. *Redox Biol.* 2014, 2, 411–429. [CrossRef]
- 7. Miyata, T.; Ueda, Y.; Horie, K.; Nangaku, M.; Tanaka, S.; Van Ypersele De Strihou, C.; Kurokawa, K. Renal catabolism of advanced glycation end products: The fate of pentosidine. *Kidney Int.* **1998**, *53*, 416–422. [CrossRef]
- Akhter, F.; Khan, M.S.; Ahmad, S. Acquired immunogenicity of calf thymus DNA and LDL modified by b-ribose: A comparative study. Int. J. Biol. Macromol. 2015, 72, 1222–1227. [CrossRef]
- 9. Indyk, D.; Bronowicka-Szydelko, A.; Gamian, A.; Kuzan, A. Advanced glycation end products and their receptors in serum of patients with type 2 diabetes. *Sci. Rep.* 2021, *11*, 13264. [CrossRef]
- 10. Kosmopoulos, M.; Drekolias, D.; Zavras, P.D.; Piperi, C.; Papavassiliou, A.G. Impact of advanced glycation end products (AGEs) signaling in coronary artery disease. *Biochim. Biophys. Acta Mol. Basis Dis.* **2019**, *1865*, 611–619. [CrossRef]
- 11. Grandhee, S.K.; Monnier, V.M. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. *J. Biol. Chem.* **1991**, *266*, 11649–11653. [CrossRef] [PubMed]
- 12. Peiretti, P.G.; Medana, C.; Visentin, S.; Giancotti, V.; Zunino, V.; Meineri, G. Determination of carnosine, anserine, homocarnosine, pentosidine and thiobarbituric acid reactive substances contents in meat from different animal species. *Food Chem.* **2011**, *126*, 1939–1947. [CrossRef]
- 13. Navarro, M.; Morales, F.J. Effect of hydroxytyrosol and olive leaf extract on 1,2-dicarbonyl compounds, hydroxymethylfurfural and advanced glycation endproducts in a biscuit model. *Food Chem.* **2017**, *217*, 602–609. [CrossRef]
- 14. Liang, Y.S.; Tang, Z.; Jiang, Y.S.; Ai, C.Y.; Peng, J.L.; Liu, Y.; Chen, J.R.; Zhang, J.Q.; Cai, Z.W. Serum metabolic changes associated with dioxin exposure in a Chinese male cohort. *Environ. Int.* **2020**, *143*, 105984. [CrossRef] [PubMed]
- Wu, Y.; Zong, M.H.; Wu, H.; He, D.; Li, L.; Zhang, X.; Zhao, D.; Li, B. Dietary advanced glycation end-products affects the progression of early diabetes by intervening in carbohydrate and lipid metabolism. *Mol. Nutr. Food Res.* 2022, *66*, 2200046. [CrossRef]
- Hu, C.Q.; Song, X.Y.; Shao, Z.Z.; Liu, Y.L.; Wang, J.; Sun, B.G. Untargeted metabolite profiling of adipose tissue in rats exposed to mepiquat. *Foods* 2023, 12, 867. [CrossRef]
- Chen, L.; Li, H.; Ru, Y.; Song, Y.; Shen, Y.; Zhao, L.; Huang, G.; Chen, Y.; Qi, Z.; Li, R.; et al. Xanthine-derived reactive oxygen species exacerbates adipose tissue disorders in male db/db mice induced by real-ambient PM2.5 exposure. *Sci. Total. Environ.* 2023, *882*, 163592. [CrossRef]
- Jiang, Y.J.; Liang, M.; Chen, L.; Wang, J.; Huang, Y.J.; Huo, H.H.; Xiao, D.R.; Hu, Y.W.; Wang, Z.; Ji, Q.Q.; et al. Myeloid SENP3 deficiency protects mice from diet and age-induced obesity via regulation of YAP1 SUMOylation. *Cell. Mol. Life Sci.* 2024, *81*, 4. [CrossRef]
- 19. Zhu, Q.Z.; An, Y.A.; Scherer, P.E. Mitochondrial regulation and white adipose tissue homeostasis. *Trends Cell Biol.* **2022**, *32*, 351–364. [CrossRef]
- Qiao, L.C.; Lin, X.; Liu, H.B.; Xiang, R.Q.; Zhan, J.M.; Deng, F.D.; Bao, M.Y.; He, H.F.; Wen, X.Y.; Deng, H.; et al. T-2 toxin induces cardiac fibrosis by causing metabolic disorders and up-regulating Sirt3/FoxO3α/MnSOD signaling pathway-mediated oxidative stress. J. Environ. Sci. 2025, 150, 532–544. [CrossRef]
- Liang, H.; Song, K. Elucidating ascorbate and aldarate metabolism pathway characteristics via integration of untargeted metabolomics and transcriptomics of the kidney of high-fat diet-fed obese mice. *PLoS ONE* 2024, 19, e0300705. [CrossRef] [PubMed]
- 22. Ling, Z.-N.; Jiang, Y.-F.; Ru, J.-N.; Lu, J.-H.; Ding, B.; Wu, J. Amino acid metabolism in health and disease. *Signal Transduct. Target. Ther.* **2023**, *8*, 345. [CrossRef] [PubMed]
- 23. Chu, C.; Liu, S.Q.; Nie, L.G.; Hu, H.M.; Liu, Y.; Yang, J. The interactions and biological pathways among metabolomics prod-ucts of patients with coronary heart disease. *Biomed. Pharmacother.* **2024**, *173*, 116305. [CrossRef]
- Quan, W.; Jiao, Y.; Xue, C.; Li, Y.; Liu, G.; He, Z.; Qin, F.; Zeng, M.; Chen, J. The effect of exogenous free N^ε-(Carboxymethyl)Lysine on diabetic-model Goto-Kakizaki rats: Metabolomics analysis in serum and urine. *J. Agric. Food Chem.* 2021, 69, 783–793. [CrossRef] [PubMed]
- 25. Ma, Q.Q.; Zhou, X.B.; Sun, Y.C.; Hu, L.L.; Zhu, J.L.; Shao, C.X.; Meng, Q.W.; Shan, A.S. Threonine, but not lysine and methionine, reduces fat accumulation by regulating lipid metabolism in obese mice. *J. Agric. Food Chem.* **2020**, *68*, 4876–4883. [CrossRef]
- Maynard, A.G.; Kanarek, N. NADH ties one-carbon metabolism to cellular respiration. *Cell Metab.* 2020, *31*, 660–662. [CrossRef]
 Holecek, M. Serine metabolism in health and disease and as a conditionally essential amino acid. *Nutrients* 2022, *14*, 1987.
- 27. Holecek, M. Serine metabolism in health and disease and as a conditionally essential amino acid. *Nutrients* **2022**, *14*, 1987. [CrossRef]
- 28. Yoo, H.C.; Yu, Y.C.; Sung, Y.; Han, J.M. Glutamine reliance in cell metabolism. Exp. Mol. Med. 2020, 52, 1496–1516. [CrossRef]
- 29. Haley, J.A.; Guertin, D.A. Adipose glutaminolysis resurfaces in metabolic disease. Nat. Metab. 2024, 6, 1200–1201. [CrossRef]
- Park, T.J.; Park, S.Y.; Lee, H.J.; Abd El-Aty, A.M.; Jeong, J.H.; Jung, T.W. α-ketoisocaproic acid promotes ER stress through impairment of autophagy, thereby provoking lipid accumulation and insulin resistance in murine preadipocytes. *Biochem. Bioph. Res. Commun.* 2022, 603, 109–115. [CrossRef]

- Ma, Q.Q.; Zhou, X.B.; Hu, L.L.; Chen, J.Y.; Zhu, J.L.; Shan, A.S. Leucine and isoleucine have similar effects on reducing lipid accumulation, improving insulin sensitivity and increasing the browning of WAT in high-fat diet-induced obese mice. *Food Funct.* 2020, 11, 2279–2290. [CrossRef]
- 32. Kuang, W.Y.; Yang, J.J.; Liu, Z.Y.; Zeng, J.Z.; Xia, X.W.; Chen, X.D.; Zhong, S.Y.; Huang, R.M. Catechin mediates ferroptosis to exert an anti-inflammatory effect on RAW 264.7 cells. *Foods* **2022**, *11*, 1572. [CrossRef] [PubMed]
- 33. Chen, Y.; Meng, Z.; Li, Y.; Liu, S.; Hu, P.; Luo, E. Advanced glycation end products and reactive oxygen species: Uncovering the potential role of ferroptosis in diabetic complications. *Mol. Med.* **2024**, *30*, 141. [CrossRef] [PubMed]
- 34. Del Olmo, A.; Calzada, J.; Nuñez, M. Benzoic acid and its derivatives as naturally occurring compounds in foods and as additives: Uses, exposure, and controversy. *Crit. Rev. Food Sci.* 2017, 57, 3084–3103. [CrossRef]
- 35. Bai, F.; Gao, G.B.; Li, T.L.; Liu, J.; Li, L.; Jia, Y.L.; Song, L.R. Integrated physiological and metabolomic analysis reveals new insights into toxicity pathways of paraquat to Microcystis aeruginosa. *Aquat. Toxicol.* **2023**, *259*, 106521. [CrossRef]
- 36. Sahu, U.; Villa, E.; Reczek, C.R.; Zhao, Z.B.; O'hara, B.P.; Torno, M.D.; Mishra, R.; Shannon, W.D.; Asara, J.M.; Gao, P.; et al. Pyrimidines maintain mitochondrial pyruvate oxidation to support de novo lipogenesis. *Science* **2024**, *383*, 1484–1492. [CrossRef]
- Rabinovich, S.; Adler, L.; Yizhak, K.; Sarver, A.; Silberman, A.; Agron, S.; Stettner, N.; Sun, Q.; Brandis, A.; Helbling, D.; et al. Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. *Nature* 2015, 527, 379–383. [CrossRef] [PubMed]
- 38. Su, L.J.; Zeng, Y.P.; Li, G.K.; Chen, J.; Chen, X.Y. Quercetin improves high-fat diet-induced obesity by modulating gut micro-biota and metabolites in C57BL/6J mice. *Phytother. Res.* 2022, *36*, 4558–4572. [CrossRef]
- 39. Arnold, P.K.; Jackson, B.T.; Paras, K.I.; Brunner, J.S.; Hart, M.L.; Newsom, O.J.; Alibeckoff, S.P.; Endress, J.; Drill, E.; Sullivan, L.B.; et al. A non-canonical tricarboxylic acid cycle underlies cellular identity. *Nature* **2022**, *603*, 477–481. [CrossRef]
- Zecchini, V.; Paupe, V.; Herranz-Montoya, I.; Janssen, J.; Wortel, I.M.N.; Morris, J.L.; Ferguson, A.; Chowdury, S.R.; Segar-ra-Mondejar, M.; Costa, A.S.H.; et al. Fumarate induces vesicular release of mtDNA to drive innate immunity. *Nature* 2023, 615, 499–506. [CrossRef]
- 41. Granot-Hershkovitz, E.; He, S.; Bressler, J.; Yu, B.; Tarraf, W.; Rebholz, C.M.; Cai, J.W.; Chan, Q.; Garcia, T.P.; Mosley, T.; et al. Plasma metabolites associated with cognitive function across race/ethnicities affirming the importance of healthy nutrition. *Alzheimers Dement.* **2023**, *19*, 1331–1342. [CrossRef] [PubMed]
- Hong, J.N.; Bhat, O.M.; Li, G.B.; Dempsey, S.K.; Zhang, Q.H.; Ritter, J.K.; Li, W.W.; Li, P.L. Lysosomal regulation of extracellular vesicle excretion during D-ribose-induced NLRP3 inflammasome activation in podocytes. *BBA-Mol. Cell Res.* 2019, 1866, 849–860.
 [CrossRef] [PubMed]
- Lu, J.J.; Tao, X.Y.; Li, M.; Zhang, X.; Zhou, Q.C.; Luo, J.X.; Zhu, T.T.; Jiao, L.F.; Jin, M. Dietary inositol improved glucose and lipid metabolism mediated by the Insulin-PI3K-Akt signaling pathway in Pacific white shrimp (*Litopenaeus vannamei*). *Aquaculture* 2023, 577, 739910. [CrossRef]
- 44. Li, Z.; Ru, S.G.; Li, J.L.; Yang, Y.J.; Wang, W.W. Continuous exposure to bisphenol S increases the accumulation of endogenous metabolic toxicants by obstructing the glucuronic acid pathway. *Environ. Pollut.* **2023**, *336*, 122433. [CrossRef]
- Zhu, Y.; Kruglikov, I.L.; Akgul, Y.; Scherer, P.E. Hyaluronan in adipogenesis, adipose tissue physiology and systemic metabolism. *Matrix Biol.* 2019, 78–79, 284–291. [CrossRef]
- Kotepui, M.; Mahittikorn, A.; Anabire, N.G.; Masangkay, F.R.; Kotepui, K.U. Malaria is associated with diminished levels of ascorbic acid: A systematic review and meta-analysis. Antioxid. *Redox Sign.* 2024, 40, 460–469. [CrossRef]
- 47. Hu, T.T.; Wu, Q.Q.; Yao, Q.; Jiang, K.B.; Yu, J.B.; Tang, Q.Z. Short-chain fatty acid metabolism and multiple effects on cardiovascular diseases. *Ageing Res. Rev.* 2022, *81*, 101706. [CrossRef]
- Gart, E.; Tengeler, A.; Morrison, M.; Kosicz, T.; Van Duyvenvoorde, W.; Kleemann, R.; Kiliaan, A. Propionic acid intervention in obese Ldlr-/-.Leiden mice attenuates NASH development, but negatively affects cognition. *Proc. Nutr. Soc.* 2020, 79, E501. [CrossRef]
- 49. Li, Z.; Yi, C.X.; Katiraei, S.; Kooijman, S.; Zhou, E.C.; Chung, C.K.; Gao, Y.Q.; Van Den Heuvel, J.K.; Meijer, O.C.; Berbée, J.F.P.; et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit. *Gut* **2018**, *67*, 1269–1279. [CrossRef]
- 50. Fan, Z.Y.; Wang, S.A.; Meng, Y.Y.; Wen, C.L.; Xu, M.X.; Li, X. Butyrate alleviates high-fat-induced metabolic disorders partially through increasing systematic glutamine. *J. Agric. Food Chem.* **2023**, *72*, 449–460. [CrossRef]
- 51. Liu, X.F.; Xu, X.M.; Zhang, T.; Xu, L.; Tao, H.L.; Liu, Y.; Zhang, Y.; Meng, X.L. Fatty acid metabolism disorders and potential therapeutic traditional Chinese medicines in cardiovascular diseases. *Phytother. Res.* **2023**, *37*, 4976–4998. [CrossRef] [PubMed]
- 52. Maiti, B.K. Cross-talk between (hydrogen)sulfite and metalloproteins: Impact on human health. *Chem.-Eur. J.* **2022**, *28*, e202104342. [CrossRef] [PubMed]
- 53. Grabner, G.F.; Xie, H.; Schweiger, M.; Zechner, R. Lipolysis: Cellular mechanisms for lipid mobilization from fat stores. *Nat. Metab.* **2021**, *3*, 1445–1465. [CrossRef]
- 54. Xu, S.J.; Lu, F.; Gao, J.H.; Yuan, Y. Inflammation-mediated metabolic regulation in adipose tissue. *Obes. Rev.* **2024**, 25, e13724. [CrossRef]
- 55. Bowman, C.E.; Rodriguez, S.; Alpergin, E.S.S.; Acoba, M.G.; Zhao, L.; Hartung, T.; Claypool, S.M.; Watkins, P.A.; Wolfgang, M.J. The mammalian malonyl-CoA synthetase ACSF3 is required for mitochondrial protein malonylation and metabolic efficiency. *Cell Chem. Biol.* **2017**, *24*, 673–684. [CrossRef]

- 56. Huang, L.L.; Gao, L.; Chen, C. Role of medium-chain fatty acids in healthy metabolism: A clinical perspective. *Trends Endocrinol. Met.* **2021**, *32*, 351–366. [CrossRef]
- 57. Haynes, V.R.; Michael, N.J.; Van Den Top, M.; Zhao, F.Y.; Brown, R.D.; De Souza, D.; Dodd, G.T.; Spanswick, D.; Watt, M.J. A neural basis for octanoic acid regulation of energy balance. *Mol. Metab.* 2020, *34*, 54–71. [CrossRef]
- Von Hanstein, A.S.; Tsikas, D.; Lenzen, S.; Jörns, A.; Plötz, T. Potentiation of lipotoxicity in human EndoC-βH1 β-Cells by glucose is dependent on the structure of free fatty acids. *Mol. Nutr. Food Res.* 2023, 67, 2200582. [CrossRef] [PubMed]
- Senyilmaz, D.; Virtue, S.; Xu, X.J.; Tan, C.Y.; Griffin, J.L.; Miller, A.K.; Vidal-Puig, A.; Teleman, A.A. Regulation of mitochondrial morphology and function by stearoylation of TFR1. *Nature* 2015, 525, 124–128. [CrossRef]
- 60. Xie, J.T.; Hou, X.N.; He, W.S.; Xiao, J.; Cao, Y.; Liu, X.J. Astaxanthin reduces fat storage in a fat-6/fat-7 dependent manner determined using high fat Caenorhabditis elegans. *Food Funct.* **2023**, *14*, 7347–7360. [CrossRef]
- 61. Yang, C.X.; Wei, J.T.; Cao, G.D.; Cai, Z.W. Lipid metabolism dysfunction and toxicity of BDE-47 exposure in white adipose tissue revealed by the integration of lipidomics and metabolomics. *Sci. Total. Environ.* **2022**, *806*, 150350. [CrossRef] [PubMed]
- Alonso-Castro, A.J.; Serrano-Vega, R.; Gutiérrez, S.P.; Isiordia-Espinoza, M.A.; Solorio-Alvarado, C.R. Myristic acid reduces skin inflammation and nociception. *J. Food Biochem.* 2022, 46, e14013. [CrossRef] [PubMed]
- Kalupahana, N.S.; Goonapienuwala, B.L.; Moustaid-Moussa, N. Omega-3 fatty acids and adipose tissue: Inflammation and browning. *Annu. Rev. Nutr.* 2020, 40, 25–49. [CrossRef] [PubMed]
- 64. Dakroub, H.; Nowak, M.; Benoist, J.F.; Noël, B.; Vedie, B.; Paul, J.L.; Fournier, N. Eicosapentaenoic acid membrane incorpo-ration stimulates ABCA1-mediated cholesterol efflux from human THP-1 macrophages. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **2021**, *1866*, 159016. [CrossRef]
- 65. Li, X.X.; Pu, Y.J.; Jiang, H.T.; Jiao, W.X.; Peng, W.J.; Tian, W.L.; Jiang, W.B.; Fang, X.M. Inhibitory effect of procyanidin B2 and tannin acid on cholesterol esterase and their synergistic effect with orlistat. *Food Sci. Hum. Well.* **2024**, *13*, 360–369. [CrossRef]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.